BloodImmunologyPeer-reviewed journal article
Pretransplant targeting of TNFRSF25 and CD25 stimulates recipient Tregs in target tissues ameliorating GVHD post-HSCT
Duneia McManusiD, Sabrina N. CopseliD, Brent J. PfeifferiD, Dietlinde WolfiD, Henry BarrerasiD, Symon MaiD, Ali KhodoriD, Seitaro KomaiiD, Marina Burgos da SilvaiD, Hajar HazimeiD, Miguel GallardoiD, Sarah Grace R Lime, Marcel R.M. van den BrinkiD, Jung‐Hyun ParkiD, Maria T. AbreuiD, Geoffrey R. HilliD, Victor L. PereziD, Robert B. LevyiD
Abstract
The current approach to minimize transplant-associated complications, including graft-versus-host disease (GVHD) includes long-term pharmacological immune suppression frequently accompanied by unwanted side effects. Advances in targeted immunotherapies regulating alloantigen responses in the recipient continue to reduce the need for pan-immunosuppression. Here, in vivo targeting of the TNF superfamily receptor 25 (TNFRSF25) and the high affinity IL-2 receptor with a TL1A-Ig fusion protein and low dose IL-2, respectively, was used to pretreat recipient mice prior to allogeneic-HSCT (aHSCT). Pretreatment induced Treg expansion persisting early post-aHSCT leading to diminished GVHD and improved transplant outcomes. Expansion was accompanied by an increase in frequency of stable and functionally active Tregs as evidenced by in vitro assays using cells from major GVHD target tissues including colon, liver, and eye. Importantly, pretreatment supported epithelial cell function/integrity, a diverse microbiome including reduction of pathologic bacteria overgrowth and promotion of butyrate producing bacteria, while maintaining physiologic levels of obligate/facultative anaerobes. Notably, using a sphingosine 1-phosphate receptor agonist to sequester T cells in lymphoid tissues, we found that the increased tissue Treg frequency included resident CD69+CD103+FoxP3+ hepatic Tregs. In contrast to infusion of donor Treg cells, the strategy developed here resulted in the presence of immunosuppressive target tissue environments in the recipient prior to the receipt of donor allo-reactive T cells and successful perseveration of GVL responses. We posit strategies that circumvent the need of producing large numbers of ex-vivo manipulated Tregs, may be accomplished through in vivo recipient Treg expansion, providing translational approaches to improve aHSCT outcomes. Graphical Abstract O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=101 SRC="FIGDIR/small/633453v1_ufig1.gif" ALT="Figure 1"> View larger version (30K): org.highwire.dtl.DTLVardef@10ef7aforg.highwire.dtl.DTLVardef@1a70f03org.highwire.dtl.DTLVardef@caa144org.highwire.dtl.DTLVardef@121b657_HPS_FORMAT_FIGEXP M_FIG C_FIG
- organism: mouse
- research focus: host-pathogen & immune response
- research focus: cancer & tumor microenvironment
- approach: experimental assay
- Citations
- 4
- FWCI
- 2.94
- Field percentile
- top 9%
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Integrated Analysis of T cell Repertoire and Transcriptome Identifies Mechanisms of Regulatory T cell (Treg) Suppression of Acute Graft-versus-Host-Disease
J. K. Lohmeyer, T. Hirai, … R. S. Negrin·bioRxiv·Jul 26, 2022
- Donor-Targeted Anti-HLA-A2 Antibody Shows Nanogram-Level Efficacy in a Novel GVHD Mouse Model
Kouta Niizuma, Alyssa H Chang, … Yusuke Nakauchi·Blood AdvancesPeer-reviewed·Jul 21, 2026
- TCF-1 in CD4 T cells regulates GVHD severity and persistence
R. Harris, M. Mammadli, … M. Karimi·bioRxiv·Mar 22, 2021
- Inhibition of ITK differentiates GVT and GVHD in allo-HSCT
M. Karimi, M. Mammadli, … A. Bah·bioRxiv·Jul 15, 2020
- Timed STING Inhibition Mitigates Gastrointestinal GvHD While Preserving Graft-versus-Leukemia Activity After Allo-HSCT
Chiara Suriano, Omer Khalid, … Hendrik Poeck·bioRxiv·Jul 21, 2026
- Poly dispersed acid-functionalized single walled carbon nanotubes target activated T and B cells to suppress GVHD in mouse model
M. B. MIA, R. K. SAXENA·bioRxiv·Feb 29, 2020